Wedbush Securities’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $685K | Buy |
5,363
+391
| +8% | +$48.8K | 0.02% | 582 |
|
|
2025
Q4 | $606K | Buy |
4,972
+348
| +8% | +$39.9K | 0.02% | 616 |
|
|
2025
Q3 | $463K | Sell |
4,624
-954
| -17% | -$85.9K | 0.02% | 680 |
|
|
2025
Q2 | $463K | Sell |
5,578
-1,099
| -16% | -$87.7K | 0.02% | 661 |
|
|
2025
Q1 | $542K | Buy |
6,677
+95
| +1% | +$8.49K | 0.02% | 585 |
|
|
2024
Q4 | $593K | Buy |
6,582
+405
| +7% | +$39.2K | 0.02% | 554 |
|
|
2024
Q3 | $610K | Sell |
6,177
-162
| -3% | -$15.9K | 0.02% | 528 |
|
|
2024
Q2 | $588K | Sell |
6,339
-1,576
| -20% | -$141K | 0.02% | 573 |
|
|
2024
Q1 | $751K | Buy |
7,915
+2,514
| +47% | +$233K | 0.03% | 490 |
|
|
2023
Q4 | $482K | Sell |
5,401
-809
| -13% | -$60.1K | 0.02% | 563 |
|
|
2023
Q3 | $453K | Sell |
6,210
-5,098
| -45% | -$407K | 0.02% | 561 |
|
|
2023
Q2 | $941K | Sell |
11,308
-1,285
| -10% | -$107K | 0.04% | 336 |
|
|
2023
Q1 | $960K | Sell |
12,593
-3,281
| -21% | -$272K | 0.05% | 328 |
|
|
2022
Q4 | $1.32M | Sell |
15,874
-5,488
| -26% | -$444K | 0.07% | 233 |
|
|
2022
Q3 | $1.69M | Buy |
21,362
+9,257
| +76% | +$780K | 0.1% | 168 |
|
|
2022
Q2 | $899K | Sell |
12,105
-2,140
| -15% | -$161K | 0.05% | 320 |
|
|
2022
Q1 | $1.28M | Sell |
14,245
-1,081
| -7% | -$99.8K | 0.06% | 281 |
|
|
2021
Q4 | $1.72M | Buy |
15,326
+1,343
| +10% | +$162K | 0.07% | 217 |
|
|
2021
Q3 | $1.76M | Buy |
13,983
+742
| +6% | +$95.6K | 0.08% | 209 |
|
|
2021
Q2 | $1.79M | Buy |
13,241
+185
| +1% | +$24.3K | 0.08% | 211 |
|
|
2021
Q1 | $1.77M | Buy |
13,056
+3,103
| +31% | +$465K | 0.1% | 184 |
|
|
2020
Q4 | $1.4M | Sell |
9,953
-4,300
| -30% | -$551K | 0.12% | 179 |
|
|
2020
Q3 | $1.59M | Buy |
14,253
+3,158
| +28% | +$354K | 0.15% | 143 |
|
|
2020
Q2 | $1.24M | Buy |
11,095
+1,125
| +11% | +$111K | 0.12% | 176 |
|
|
2020
Q1 | $772K | Sell |
9,970
-344
| -3% | -$30.5K | 0.09% | 239 |
|
|
2019
Q4 | $981K | Sell |
10,314
-209
| -2% | -$18.1K | 0.09% | 255 |
|
|
2019
Q3 | $802K | Sell |
10,523
-372
| -3% | -$30.9K | 0.08% | 287 |
|
|
2019
Q2 | $956K | Sell |
10,895
-887
| -8% | -$75.7K | 0.1% | 241 |
|
|
2019
Q1 | $1.07M | Buy |
11,782
+7,810
| +197% | +$664K | 0.11% | 211 |
|
|
2018
Q4 | $285K | Buy |
+3,972
| New | +$320K | 0.04% | 556 |
|
|
2017
Q4 | – | Sell |
-7,807
| Closed | -$676K | – | 906 |
|
|
2017
Q3 | $676K | Buy |
7,807
+2,589
| +50% | +$208K | 0.09% | 269 |
|
|
2017
Q2 | $403K | Buy |
+5,218
| New | +$370K | 0.05% | 449 |
|
|
2015
Q2 | – | Sell |
-4,803
| Closed | -$361K | – | 776 |
|
|
2015
Q1 | $361K | Buy |
+4,803
| New | +$336K | 0.06% | 367 |
|
|
2013
Q4 | – | Sell |
-11,265
| Closed | -$485K | – | 618 |
|
|
2013
Q3 | $485K | Buy |
11,265
+1,638
| +17% | +$66.4K | 0.13% | 192 |
|
|
2013
Q2 | $335K | Buy |
+9,627
| New | +$338K | 0.09% | 266 |
|
Other funds holding XBI
Wedbush Securities's XBI Position: Q1 2026 in Review
Wedbush Securities increased its State Street SPDR S&P Biotech ETF (XBI) stake by 7.9% in Q1 2026, buying an estimated $48.8K and bringing the position to 5,363 shares worth $685K. The position accounts for 0.02% of the portfolio, ranked #582.
Wedbush Securities first reported a position in XBI in Q2 2013 and has held it in 35 quarters since. The position peaked at $1.79M in Q2 2021. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Wedbush Securities held 5,363 shares of State Street SPDR S&P Biotech ETF worth $685K as of Q1 2026.
- Wedbush Securities bought 391 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $48.8K.
- State Street SPDR S&P Biotech ETF made up 0.02% of Wedbush Securities's portfolio in Q1 2026, its #582 holding.
- Wedbush Securities first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 35 quarters since.
- Wedbush Securities's State Street SPDR S&P Biotech ETF position peaked at $1.79M in Q2 2021.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Wedbush Securities's 13F filing for Q1 2026, filed 21 Apr 2026.